capecitabine has been researched along with Paraganglioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashwathanarayana, AG; Biswal, CK; Kapoor, R; Mittal, BR; Parihar, AS; Sood, A | 1 |
| Borson-Chazot, F; Giraud, S; Joly, MO; Lombard-Bohas, C; Nozières, C; Riou, JP; Scoazec, JY; Simon, C; Walter, T | 1 |
2 other study(ies) available for capecitabine and Paraganglioma
| Article | Year |
|---|---|
Imaging-Guided Use of Combined
Topics: Adult; Capecitabine; Combined Modality Therapy; Fluorodeoxyglucose F18; Humans; Male; Mediastinal Neoplasms; Neoplasm Metastasis; Octreotide; Organometallic Compounds; Paraganglioma; Positron Emission Tomography Computed Tomography; Radiotherapy, Image-Guided | 2017 |
A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Dacarbazine; Deoxycytidine; Drug Synergism; Fluorouracil; Humans; Immunohistochemistry; Male; Paraganglioma; Retroperitoneal Neoplasms; Succinate Dehydrogenase; Temozolomide; Treatment Outcome | 2012 |